Patient characteristics
. | Data . |
---|---|
No. patients | 38 |
No. men/no. women | 18/20 |
Age, median y (range) | 62 (21-87) |
Subtype, no. | |
Acute | 23 |
Chronic | 12 |
Smoldering | 3 |
WBC, median × 109/L (range) | 8.4 (1.5-47.94) |
Abnormal lymphocytes, median % (range) | 15 (1-78) |
LDH, median IU/L (range) | 561 (204-4141) |
Hypercalcemia, no. | |
No | 33 |
Yes | 5 |
PS, no. | |
0 | 17 |
1 | 8 |
2 | 6 |
3 | 3 |
4 | 4 |
Response to chemotherapy, no. | |
PR | 14 |
CR | 2 |
PD | 7 |
. | Data . |
---|---|
No. patients | 38 |
No. men/no. women | 18/20 |
Age, median y (range) | 62 (21-87) |
Subtype, no. | |
Acute | 23 |
Chronic | 12 |
Smoldering | 3 |
WBC, median × 109/L (range) | 8.4 (1.5-47.94) |
Abnormal lymphocytes, median % (range) | 15 (1-78) |
LDH, median IU/L (range) | 561 (204-4141) |
Hypercalcemia, no. | |
No | 33 |
Yes | 5 |
PS, no. | |
0 | 17 |
1 | 8 |
2 | 6 |
3 | 3 |
4 | 4 |
Response to chemotherapy, no. | |
PR | 14 |
CR | 2 |
PD | 7 |
LDH indicates lactose dehydrogenase; PR, partial response; CR, complete response; and PD, progressive disease.